Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25692969 | 0.90 | NOD1 (0.47) | OTCNOD1GLP1RTDP1 | |
| SCHEMBL15276505 | 0.90 | OTC (0.45) | OTCNOD1FOLH1GLP1RTDP1 | |
| SCHEMBL29425539 | 0.89 | OTC (0.51) | OTCNOD1GLP1RTDP1 | |
| SCHEMBL19801989 | 0.88 | GLP1R (0.45) | OTCNOD1FOLH1GLP1RNOS3 | |
| SCHEMBL26076479 | 0.87 | OTC (0.45) | OTCNOD1FOLH1GLP1RTDP1 | |
| SCHEMBL24593048 | 0.86 | OTC (0.44) | OTCNOD1FOLH1GLP1RTDP1 | |
| SCHEMBL24796091 | 0.85 | NOD1 (0.48) | OTCNOD1GLP1RTDP1 | |
| SCHEMBL21738833 | 0.85 | OTC (0.49) | OTCNOD1GLP1RTDP1KDM4E | |
| SCHEMBL29221102 | 0.85 | OTC (0.49) | OTCNOD1GLP1RTDP1KDM4E | |
| SCHEMBL24229748 | 0.85 | OTC (0.49) | OTCNOD1GLP1RTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| US-11041000-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210009638-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-10196424-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10023614-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| WO-2018089693-A2 | METHODS FOR DETERMINING AND MONITORING GASTROINTESTINAL INFLAMMATION | PROTAGONIST THERAPEUTICS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180079783-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180022778-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079783-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | OTC 3996/4885NOD1 50/4885FOLH1 762/4885 |
| US-11041000-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | OTC 4590/4885NOD1 86/4885FOLH1 640/4885 |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | OTC 828/4885NOD1 1132/4885FOLH1 1596/4885 |
| US-10023614-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | IL23R, IL1RN, VIP | OTC 2627/4885NOD1 112/4885FOLH1 481/4885 |
| US-10196424-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | IL23R, IL1RN, VIP | OTC 2627/4885NOD1 112/4885FOLH1 481/4885 |
| US-20180022778-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | OTC 3996/4885NOD1 50/4885FOLH1 762/4885 |
| US-20210009638-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | OTC 4590/4885NOD1 86/4885FOLH1 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.